May 14, 2014 by Patricia Silva, PhD Risk of Neurodegenerative Diseases Such As Multiple Sclerosis Affected By Gene Expression, Immune System Response The diagnosis of a disease normally depends on the risk factors one is exposed to during his or her lifetime, and subsequently therapeutic measures are taken in order to treat the same with hopes of a better prognosis and a healthy lifestyle. However, scientists at the Brigham and Women’s Hospital…
May 13, 2014 by Maureen Newman Brain Receptor More Common to Women May Explain Sex Disparity in Multiple Sclerosis For years, clinicians and patients could only notice and accept the fact that four times more women than men are diagnosed with multiple sclerosis. Now, a group of researchers from Washington University School of Medicine in St. Louis are uncovering a potential reason for the disparity, and they recently…
May 11, 2014 by Patricia Silva, PhD Low Fat Diets Benefit Multiple Sclerosis Patients, According To New Study A small scale study undertaken by researchers at the Department of Neurology, Oregon Health & Science University (OSHU) showed the benefits of maintaining a low-fat diet in improving fatigue related to multiple sclerosis (MS). The study was led by Dr. Vijayshree Yadav, M.D., an associate professor of neurology in…
May 9, 2014 by Maureen Newman Sun Pharma-Sponsored Phase 3 Trial to Treat Spasticity Due to Multiple Sclerosis in Recruiting Patients One of the most common and troublesome symptoms of multiple sclerosis is spasticity. Patients with spasticity experience involuntary muscle spasms and muscle stiffness, which interfere with daily activities. An imbalance in the signals from the brain and spinal cord in the central nervous system increase the excitability of muscles,…
May 6, 2014 by admin Combined Multiple Sclerosis Therapy Using Copaxone Relieves RRMS Symptoms In Study Although the biological activity by which Copaxone (glatiramer) exerts its effects i multiple sclerosis (MS) patients is not fully understood, it is believed it can block the induction of autoimmune encephalomyelitis as observed in recent experiments with mice. Research in animals and in vitro systems suggest that glatiramer acetate-specific suppressor…
May 5, 2014 by Maureen Newman Targeting B-cell Activity May Reduce MS Brain Lesions, According To GlaxoSmithKline-Backed Study New research work from GlaxoSmithKline presented by Daren Ausin, PhD, at the American Academy of Neurology’s 66th Annual Meeting has implications for individuals with relapsinig-remitting multiple sclerosis. The presentation detailed a study that used GlaxoSmithKline’s ofatumumab in 231 patients with relapse-remitting multiple sclerosis. Ofatumumab is an anti-B-cell antibody, and it…
May 2, 2014 by BioNews Staff New Multiple Sclerosis Drug Target of U.S. and Japanese Researchers The National Center of Neurology and Psychiatry, based in Japan, announced that they will initiate a 3-month clinical trial on 9 patients with multiple sclerosis, beginning in March. Multiple sclerosis is an autoimmune disease caused by mutations of lymphocyte immune cells, which attack and destroy a patient’s own nerve cells. Patients with multiple sclerosis typically…
April 29, 2014 by admin New Report Cautions Marijuana As Treatment For MS Marijuana has been approved for medicinal purposes in a number of U.S. states, however it still remains a much debated issue according to the American Academy of Neurology. New information has been released by ANN Annual Meeting in Philadelphia, PA. This represents the largest gathering of neurologists globally. According…
April 28, 2014 by Maureen Newman Knockdown of Retinoblastoma Enhances Nerve Regeneration in Multiple Sclerosis & Other Diseases Nerve cells are notoriously difficult to regenerate, but according to a recent article in Science Daily, a research group from University of Galgary’s Hotchkiss Brain Institute (HBI) has discovered a new way to turn on neural cell growth, which would be beneficial for treating nerve damage commonly found in diseases…
April 21, 2014 by Charles Moore Supreme Court Denies Injunction Request To Block Release Of Generic MS Drug, But Patent Fight Not Over Yet Petah Tikvah Israel-based Teva Pharmaceutical Industries Ltd. has suffered a setback in its fight to forestall release of generic competitors for its proprietary Copaxone Multiple Sclerosis drug. However, the company is expressing optimism that potential for recovery of Patent Infringement Damages may dissuade aspirant generic competitors from proceeding until a…
